Literature DB >> 2591462

Interconversion between haloperidol and reduced haloperidol in healthy volunteers.

B S Chakraborty1, J W Hubbard, E M Hawes, G McKay, J K Cooper, T Gurnsey, E D Korchinski, K K Midha.   

Abstract

The interconversion between haloperidol (HAL) and reduced haloperidol (RHAL) was examined following their separate administration in low (5 mg) single oral doses to 15 young healthy male volunteers in a crossover design. Using an ultrasensitive HPLC method plasma concentrations of HAL and RHAL were monitored over a period of one week following each administration. Except in one case, both the analytes were found in the plasma of all the volunteers following each administration, thereby indicating interconversion of the two compounds. Comparison of the AUC(0-t) ratios of RHAL/HAL and HAL/RHAL following administration of HAL and RHAL, respectively, revealed that the interconversion favours the reduction of HAL to RHAL. The disposition of HAL following administration of RHAL appears to be limited by its rate of formation and the disposition of RHAL following administration of HAL, on the other hand, is much slower than that of the parent compound.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2591462     DOI: 10.1007/bf00609423

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  12 in total

1.  Interconversion between haloperidol and reduced haloperidol in humans.

Authors:  K K Midha; E M Hawes; J W Hubbard; E D Korchinski; G McKay
Journal:  J Clin Psychopharmacol       Date:  1987-10       Impact factor: 3.153

2.  Haloperidol metabolism and antipsychotic effect in schizophrenia.

Authors:  A C Altamura; M C Mauri; R Cavallaro; A Gorni
Journal:  Lancet       Date:  1987-04-04       Impact factor: 79.321

3.  A liner mode of reversible metabolism and its application to bioavailability assessment.

Authors:  S Hwang; K C Kwan; K S Albert
Journal:  J Pharmacokinet Biopharm       Date:  1981-12

4.  Isolation and identification of a metabolite of haloperidol.

Authors:  B E Pape
Journal:  J Anal Toxicol       Date:  1981 May-Jun       Impact factor: 3.367

5.  Distribution excretion and metabolism of neuroleptics of the butyrophenone type. II. Distribution, excretion and metabolism of haloperidol in Sprague-Dawley rats.

Authors:  G A Braun; G I Poos; W Soudijn
Journal:  Eur J Pharmacol       Date:  1967-01       Impact factor: 4.432

6.  Electrophysiological interactions between haloperidol and reduced haloperidol, and dopamine, norepinephrine and phencyclidine in rat brain.

Authors:  D G Kirch; M R Palmer; M Egan; R Freedman
Journal:  Neuropharmacology       Date:  1985-05       Impact factor: 5.250

7.  Intersubject variation in the pharmacokinetics of haloperidol and reduced haloperidol.

Authors:  K K Midha; B S Chakraborty; D A Ganes; E M Hawes; J W Hubbard; D L Keegan; E D Korchinski; G McKay
Journal:  J Clin Psychopharmacol       Date:  1989-04       Impact factor: 3.153

8.  Haloperidol and reduced haloperidol plasma levels in selected schizophrenic patients.

Authors:  L Ereshefsky; C M Davis; C A Harrington; M W Jann; J L Browning; S R Saklad; N R Burch
Journal:  J Clin Psychopharmacol       Date:  1984-06       Impact factor: 3.153

9.  The determination of essential clearance, volume, and residence time parameters of recirculating metabolic systems: the reversible metabolism of methylprednisolone and methylprednisone in rabbits.

Authors:  W F Ebling; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1986-12

10.  Reduced haloperidol: effects on striatal dopamine metabolism and conversion to haloperidol in the rat.

Authors:  E R Korpi; R J Wyatt
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

View more
  12 in total

1.  Failure to respond to treatment with typical antipsychotics is not associated with CYP2D6 ultrarapid hydroxylation.

Authors:  K J Aitchison; J Munro; P Wright; S Smith; A J Makoff; C Sachse; P C Sham; R M Murray; D A Collier; R W Kerwin
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

2.  Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients.

Authors:  H K Roh; J Y Chung; D Y Oh; C S Park; J O Svensson; M L Dahl; L Bertilsson
Journal:  Br J Clin Pharmacol       Date:  2001-09       Impact factor: 4.335

3.  Pharmacokinetics of haloperidol and reduced haloperidol in Chinese schizophrenic patients after intravenous and oral administration of haloperidol.

Authors:  W H Chang; Y W Lam; M W Jann; H Chen
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 4.  Reduced haloperidol: a factor in determining the therapeutic benefit of haloperidol treatment?

Authors:  W H Chang
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 5.  Pharmacokinetics of haloperidol: an update.

Authors:  S Kudo; T Ishizaki
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

Review 6.  Haloperidol dosing strategies in the treatment of delirium in the critically ill.

Authors:  Erica H Z Wang; Vincent H Mabasa; Gabriel W Loh; Mary H H Ensom
Journal:  Neurocrit Care       Date:  2012-02       Impact factor: 3.210

7.  Reversible metabolism of haloperidol and reduced haloperidol in Chinese schizophrenic patients.

Authors:  M W Jann; Y W Lam; W H Chang
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

8.  Synthesis of the enantiomers of reduced haloperidol.

Authors:  J C Jaen; B W Caprathe; S Priebe; L D Wise
Journal:  Pharm Res       Date:  1991-08       Impact factor: 4.200

9.  Effect of quinidine on the interconversion kinetics between haloperidol and reduced haloperidol in humans: implications for the involvement of cytochrome P450IID6.

Authors:  D Young; K K Midha; M J Fossler; E M Hawes; J W Hubbard; G McKay; E D Korchinski
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

10.  Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine/debrisoquine monooxygenase).

Authors:  R F Tyndale; W Kalow; T Inaba
Journal:  Br J Clin Pharmacol       Date:  1991-06       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.